knowledge -WSS

knowledge

author：leisure time 2025-08-23 03:45:31 - browse：98142

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： 5 ways to address the shortage of health care workers

leisure time

WSS

Neuroscience renaissance leads to new crop of psychiatric drugs

Lecanemab for Alzheimer's is coming. Is the health system ready?

CDC advisory group OKs chikungunya vaccine

Neuroscience renaissance leads to new crop of psychiatric drugs

California’s proposed $25 per hour health care minimum wage

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

explore

knowledge

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HCA discloses massive data breach affecting 11 million patients

Malaria cases in Florida and Texas: Here’s what you need to know

How the political right came to back psychedelics to treat trauma

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Neuroscience renaissance leads to new crop of psychiatric drugs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Charles Manson follower Leslie Van Houten released from prison after 53 years

Walensky prepares to leave CDC — and Congress — behind

What to know about OceanGate, the company behind the missing Titanic submersible

Wikipedia

Retired US general questions alleged Putin, Prigozhin meeting

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

CDC panel: People 65 and older should get a Covid spring booster shot

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Charles Manson follower Leslie Van Houten released from prison after 53 years

Petition to FDA: Get the lead out of consumer hair dyes

leisure time

leisure time

hotspot

knowledge